{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:05:32Z","timestamp":1790683532696,"version":"4.1.0"},"reference-count":20,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: Retinopathy of prematurity (ROP) is a significant cause of blindness in infants. Appropriate therapeutic intervention is essential because retinal detachment due to the progression of ROP is critical to visual function. The intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has been increasingly applied to inhibit the development and progression of ROP. In this study, we compared the efficacy of single intravitreal bevacizumab (IVB) and ranibizumab (IVR) injections for the treatment of ROP. Methods: A total of 39 eyes in 21 patients with severe ROP and IVB (15 eyes of 8 patients) and IVR (24 eyes of 13 patients) were retrospectively reviewed. Patient background, the severity of ROP, and the percentage of cases in which ROP regressed without additional treatment were compared between the two groups. Results: Patient background and ROP severity were not significantly different between the two groups. Recurrence was observed in one eye of one patient in the IVB group, and thirteen eyes in seven patients in the IVR group required additional laser photocoagulation, which was significantly different in the two groups (p &lt; 0.01, Fisher\u2019s exact test). In the IVR group, two eyes of two patients underwent vitreous surgery. Conclusion: Compared with IVR, IVB is likely to control the severity of ROP with a single treatment.<\/jats:p>","DOI":"10.3390\/children11080927","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:38:20Z","timestamp":1722515900000},"page":"927","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Single-Treatment Efficacy of Bevacizumab and Ranibizumab for Retinopathy of Prematurity"],"prefix":"10.3390","volume":"11","author":[{"given":"Fumio","family":"Takano","sequence":"first","affiliation":[{"name":"Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6100-349X","authenticated-orcid":false,"given":"Kaori","family":"Ueda","sequence":"additional","affiliation":[{"name":"Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yamada-Nakanishi","sequence":"additional","affiliation":[{"name":"Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6464-4302","authenticated-orcid":false,"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41433-020-1101-z","article-title":"Causes of severe visual impairment in infants and methods of management","volume":"35","author":"Ustunyurt","year":"2021","journal-title":"Eye"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41598-021-80989-z","article-title":"Nationwide incidence and treatment pattern of retinopathy of prematurity in South Korea using the 2007\u20132018 national health insurance claims data","volume":"11","author":"Hong","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3928\/23258160-20170630-06","article-title":"The epidemiology of retinopathy of prematurity in the United States","volume":"48","author":"Ludwig","year":"2017","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity; a review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/archopht.118.5.645","article-title":"Involution of retinopathy of prematurity. Cryotherapy for retinopathy of prematurity cooperative group","volume":"118","author":"Repka","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17469899.2019.1596026","article-title":"A review of treatment for retinopathy of prematurity","volume":"14","author":"Hansen","year":"2019","journal-title":"Expert Rev. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0420.2005.00548.x","article-title":"Laser photocoagulation for retinopathy of prematurity; structural and functional outcome","volume":"84","author":"Kieselbach","year":"2006","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group (2003). Revised indications for the treatment of retinopathy of prematurity; results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol., 121, 1684\u20131694.","DOI":"10.1001\/archopht.121.12.1684"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1167\/iovs.13-11765","article-title":"Development of refractive error in individual children with regressed retinopathy of prematurity","volume":"54","author":"Wang","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW); an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity; the firefleye randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"International Committee for Classification of Retinopathy of Prematurity (2005). The International Classification of Retinopathy of Prematurity revisited. Arch. Ophthalmol., 123, 991\u2013999.","DOI":"10.1001\/archopht.123.7.991"},{"key":"ref_14","first-page":"2311","article-title":"Profile of conbercept in the treatment of neovascular age-related macular degeneration","volume":"9","author":"Lu","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Spandau, U., and Kim, S.J. (2019). Pediatric Retinal Vascular Diseases; From Angiography to Vitrectomy, Springer. [1st ed.]. Chapter 17.","DOI":"10.1007\/978-3-030-13701-4"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000449530","article-title":"The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity; a comparison study between ranibizumab and bevacizumab","volume":"236","author":"Cevher","year":"2016","journal-title":"Ophthalmologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr. Eye Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/8\/927\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:27:00Z","timestamp":1760110020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/8\/927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["children11080927"],"URL":"https:\/\/doi.org\/10.3390\/children11080927","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}